Results demonstrate Esopredict’s ability to predict the likelihood of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett’s esophagus. BALTIMORE, Aug. 15, 2024 /PRNewswire/ — Previse, a gastrointestinal health company, announced today that […]
